Can you assess both earlyâ and lateâphase asthmatic responses?

Absolutely. Depending on your objectives, we can measure immediate airway responses to bronchoconstrictors as well as lateâphase inflammatory reactions through timeâcourse sampling and functional tests.

Contract Research Solutions for Respiratory Diseases

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Asthma Model Development Services

Q: Do you offer models that mimic steroidâresistant asthma?

Yes. Our HDM + LPS model (or chronic HDM + lowâdose LPS) typically exhibits reduced responsiveness to corticosteroids, making it suitable for testing novel steroidâsparing or steroidâresistant asthma therapeutics.

Inquiry

Ace Therapeutics specializes in preclinical contract research organization services with a deep focus on respiratory diseases. Our core offering is the development, validation, and application of sophisticated in vivo asthma models that serve as powerful tools for investigating disease mechanisms and evaluating novel therapeutic candidates. We understand that a well-characterized, physiologically relevant animal model is the cornerstone of successful translational research. Our services are designed to provide you with robust, reliable data, bridging the gap between early-stage discovery and clinical development.

The Critical Role of Preclinical Asthma Models in Drug Development

Asthma is a complex, heterogeneous inflammatory airway disease characterized by variable airflow obstruction, airway hyperresponsiveness (AHR), and underlying immune dysregulation. Recapitulating these key features in a preclinical setting is essential for generating meaningful data. A poorly chosen or inadequately characterized model can lead to inconclusive results, failed translation, and costly late-stage setbacks.

Our team of respiratory disease biologists and pharmacologists collaborates with you to select or design an asthma model that best aligns with your compound's mechanism of action (MoA) and your specific research questions. We focus on generating clinically translatable endpoints that offer predictive value for human efficacy.

Customized Asthma Models for Diverse Research Needs

We understand that no single model fits all drug development programs. Our team works closely with you to design, establish, and validate the most appropriate asthma model based on your research question, desired disease phenotype, and preferred species. Below is a selection of commonly used models; however, we routinely adapt or combine protocols to create unique models (e.g., transgenic backgrounds, alternative allergens, steroid-resistant variants).

Commonly Utilized Asthma Models

Model Category	Inducer/Protocol	Species	Key Features	Typical Applications
Acute Allergic Asthma	Ovalbumin (OVA) sensitization + challenge	Mouse, Rat	Th2-driven eosinophilic inflammation, elevated IgE, IL-4/IL-5/IL-13	Anti-inflammatory drug screening, mechanism studies
Chronic Allergic Asthma	Repeated House Dust Mite (HDM) extract challenges (≥5 weeks)	Mouse	Airway remodeling (collagen deposition, goblet cell hyperplasia), sustained AHR, mucus hypersecretion	Efficacy testing for chronic treatment, anti-remodeling agents
Mixed Granulocytic (Neutrophilic) Asthma	HDM + low-dose LPS	Mouse	Neutrophilic infiltration, Th1/Th17 profile, relative steroid resistance	Steroid-resistant asthma therapeutics
Viral Exacerbation Model	HDM sensitization + viral mimic (Poly I:C) or live virus (e.g., Respiratory Syncytial Virus, Influenza)	Mouse	Enhanced airway inflammation, worsened AHR, mimicking clinical exacerbation	Exacerbation prevention or treatment
Occupational Asthma	Toluene diisocyanate (TDI) or other chemical sensitizers	Mouse, Rat	Mixed eosinophilic/neutrophilic inflammation, chemical-induced airway hyperreactivity	Chemical-induced asthma research
Allergen-induced Remission & Relapse	Alternaria alternata or HDM with rest and re-challenge	Mouse	Mimics relapsing human disease, remodeling features	Long-term management strategies

We are not limited to the models above—contact us to discuss your specific requirements (e.g., different allergens, genetically modified mice, alternative challenge routes).

Service Category	Description & Key Endpoints
Airway Hyperresponsiveness (AHR)	Non-invasive whole-body plethysmography (PenH) or invasive lung function measurements (FlexiVent) to evaluate resistance and compliance upon methacholine challenge.
Bronchoalveolar Lavage Fluid (BALF) Analysis	Total and differential cell counts (eosinophils, neutrophils, macrophages, lymphocytes). Cytokine/chemokine profiling (IL-4, IL-5, IL-13, IL-17, IFN-γ, eotaxin, etc.) – using multiplex assay technology. Albumin or LDH measurement to assess lung injury.
Histopathology & Immunohistochemistry	H&E staining for inflammatory cell infiltration. PAS/AB staining to quantify mucus production and goblet cell metaplasia. Masson's Trichrome or Sirius Red for collagen deposition (airway remodeling). Immunostaining for specific immune cell markers (e.g., eosinophils, neutrophils, T cell subsets) or signaling molecules.
Inflammatory Mediators in Serum/Lung Homogenates	Total and allergen-specific IgE, Th2/Th17 cytokines, and other soluble mediators.
Gene Expression Analysis	qRT-PCR for mucin genes (Muc5ac, Gob5), inflammatory cytokines, and remodeling factors.
Integrated PK/PD Sampling	Optional pharmacokinetic sampling to correlate drug exposure with efficacy endpoints.
Biomarker Exploration	Support for exploratory biomarker analysis to inform clinical translation.

Our Service Process

We follow a collaborative, step‑by‑step approach to ensure that the final study design aligns perfectly with your preclinical objectives.

Scientific Consultation & Protocol Design
Model Establishment & Validation
In Vivo Efficacy Study
Sample Collection & Data Analysis
Post‑Study Support

Why Choose Ace Therapeutics for Asthma Model Development?

Deep Respiratory Expertise: Our team possesses extensive hands‑on experience with asthma pathology and diverse animal models, ensuring your study is designed with scientific rigor.
Unmatched Customization: We adapt every parameter: allergen type (HDM, OVA, ragweed, aspergillus, etc.), sensitization protocol, challenge frequency, species/strain, and genetic background.
End‑to‑End Solutions: From model development through to multi‑parameter efficacy readouts, we eliminate the need for multiple vendors and streamline your research.
Quality‑Driven Practices: All studies follow detailed standard operating procedures, with randomized group allocation, blinded analyses where applicable, and thorough documentation.
Transparent Communication: Regular project updates and open dialogue allow you to stay informed and make timely decisions.

Contact Ace Therapeutics to discuss how our customized asthma models and comprehensive downstream services can accelerate your drug development. Our scientific team is ready to provide expert guidance tailored to your unique project.

Frequently Asked Questions (FAQs)

What asthma models can you develop beyond those listed in the table?

We specialize in custom model development. Clients may request models using different allergens (e.g., ragweed, cockroach, Aspergillus), alternative challenge routes (intranasal, inhalation, intratracheal), or genetically modified mice on specific backgrounds. Please contact us to discuss your needs.

Do you provide model validation data before starting efficacy studies?

Yes. We typically conduct a pilot study or include validation groups to confirm successful model establishment (e.g., verifying airway inflammation, AHR) prior to full‑scale efficacy testing. This ensures your drug is evaluated in a well‑characterized system.

Can you assess both early‑ and late‑phase asthmatic responses?

Absolutely. Depending on your objectives, we can measure immediate airway responses to bronchoconstrictors as well as late‑phase inflammatory reactions through time‑course sampling and functional tests.

What types of compounds can be tested in your asthma models?

We have experience with small molecules, biologics (antibodies, cytokines), peptides, and even cell therapies. Our models accommodate various dosing routes (i.v., i.p., s.c., inhalation, intranasal) and regimens.

How do you ensure the reproducibility of model results?

Our experiments follow detailed protocols with controlled environmental conditions, age‑matched animals, randomized group allocation, and blinded analyses where appropriate. We provide full documentation for transparency and reliability.

Do you offer models that mimic steroid‑resistant asthma?

Yes. Our HDM + LPS model (or chronic HDM + low‑dose LPS) typically exhibits reduced responsiveness to corticosteroids, making it suitable for testing novel steroid‑sparing or steroid‑resistant asthma therapeutics.